| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
NOTTINGHAM, U.K.—In late 2017, Quotient Sciences, a drug development services organization, announced it had acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K. The acquisition strengthens and expands Quotient’s formulation and manufacturing services footprint in the United Kingdom and further supports the growth of Quotient’s Translational Pharmaceutics platform, following the acquisitions of SeaView Research and QS Pharma in February 2017.
 
Pharmaterials has a significant track record in supporting the development of small-molecule drug products for oral and inhaled delivery, according to Quotient. The company’s portfolio of services spans the characterization and optimization of drug substance physical forms, the development of preclinical and clinical formulations, through to clinical trial manufacturing and subsequent global drug product supply. The business was founded in 2000 and is located in a 48,000-square-foot facility that houses 13 GMP manufacturing suites, with space for future expansion.
 
Mark Egerton, CEO of Quotient Sciences, said: “The acquisition of Pharmaterials strengthens Quotient’s service portfolio from preclinical formulation development through to commercial manufacturing. The addition expands Quotient’s global CDMO services with added capacity and capabilities to better serve our clients’ needs.”

Related Topics

Published In

Volume 14 - Issue 1 | January 2018

January 2018

January 2018 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Clear sample tubes are shown in a clear tote with red lids in a sample prep robot with a blue and silver industrial lab background.

The crucial role of sample preparation in biotherapy manufacturing

Discover how better sample preparation can unlock improved assay accuracy and analytical results.
A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Three burgundy round and linear conformations of oligonucleotides are shown against a black background.

Accelerating RNA therapeutic testing with liver microphysiological platforms

Researchers can now study oligonucleotide delivery and efficacy in a system that models a real human liver.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue